InNexus Biotechnology, Inc.

IXSBF · OTC
Analyze with AI
6/30/2010
6/30/2009
6/30/2008
6/30/2007
Revenue$0$0$1$15
% Growth-100%-93.4%
Cost of Goods Sold$468$453$610$242
Gross Profit$0$0-$610-$242
% Margin-60,403.4%-1,583.8%
R&D Expenses$1,156$2,305$3,813$2,129
G&A Expenses$2,280$4,397$0$0
SG&A Expenses$2,280$4,397$4,610$3,658
Sales & Mktg Exp.$0$0$0$0
Other Operating Expenses$494-$2,777-$2,710-$639
Operating Expenses$3,930$6,702$5,713$5,148
Operating Income-$3,930-$6,702-$5,712-$5,133
% Margin-565,567.3%-33,603.6%
Other Income/Exp. Net$3,930-$1,095-$351-$121
Pre-Tax Income$0$0$0$0
Tax Expense$0$0$0$0
Net Income-$6,689-$8,017-$5,888-$5,172
% Margin-582,934.9%-33,861.5%
EPS-0.07-0.11-0.11-0.13
% Growth36.4%0%15.4%
EPS Diluted-0.07-0.11-0.11-0.13
Weighted Avg Shares Out96,33775,28755,25943,943
Weighted Avg Shares Out Dil96,33775,28755,25943,943
Supplemental Information
Interest Income$1$3$77$159
Interest Expense$2,794$1,314$253$199
Depreciation & Amortization$988$410$502$242
EBITDA-$2,942-$6,293-$5,210-$5,497
% Margin-515,888.8%-35,991.8%